Comparative study of the safety and efficacy of levofloxacin and ciprofloxacin in the treatment of community-acquired, bacterial urinary tract infection among patients with chronic kidney disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202401622249032

Enrollment

Registered

2024-01-16

Start date

2022-10-28

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary tract infection, Chronic kidney disease Kidney Disease

Interventions

Ciprofloxacin

Levofloxacin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age 18years and above. 2. Known CKD patients 3. Symptoms compatible with a diagnosis of UTI plus positive dipstick test for pyuria 4. Informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Patients with any rapidly progressive or terminal disease 2. Individuals with prior renal transplantation. 3. Co-existence of other infections in addition to urinary tract infection 4. Exposure to any antimicrobial prior to presentation 5. Known previous reaction to quinolones. 6. Hospital acquired UTI 7. Catheter associated UTI

Design outcomes

Primary

Measure	Time frame
1.Efficacy as determined by clinical resolution, clearance of signs and symptoms 2.Tolerability of drug as determined by Treatment Emergent Symptoms and Signs (TESS)	—

Secondary

Measure	Time frame
1. Duration of hospital stay and/or hospitalization and/or re-hospitalization 2. Rate of re-occurrence of UTI and/or any bacterial infections during the subsequent 3 months of follow up. 3. All-cause mortality among participants	—

Countries

Nigeria

Contacts

Public ContactAdebayo Dhikrullah

Senior Registrar

adeyemidhik@gmail.com+2348038634007

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026